Methods for Fertility Preservation: Impact of Vitrification on in Vitro Matured Oocytes
NCT ID: NCT03680937
Last Updated: 2018-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
240 participants
OBSERVATIONAL
2018-09-20
2020-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
According to the recent data of the literature, it remains unclear whether the vitrification of ovocytes must be performed before or after in vitro maturation (IVM). Therefore the aim of this study is to study the impact on structure and functions of ovocytes when vitrification is performed before or after IVM. The vitrification will be performed by a semi-automatic method which is an innovative method.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Vitrification Effect Before or After In Vitro Maturation
NCT03416400
Preservation of Women's Fertility: Evaluation of Innovative Methods for Ovarian Tissue Cryopreservation
NCT06724471
Validation of Donor Oocytes Semi-automated Vitrification
NCT06238570
Interest of Automated Oocyte Freezing
NCT03570073
Vitrification for Ovarian Tissue Harvesting
NCT03649087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The immature oocytes provide from ICSI patients. In routine these oocytes (germinal vesicle) are normally destroyed because they cannot be used for injection. The women will give an informed and written consent. Inclusion criteria are women less 37 years without dysovulation.
The vitrification will be performed with the semi-automatic method (Gavi, Merck). The kinetic and maturation rate will be analysed by time lapse (Primovision, Vitrolife) In the mature oocytes, the actin and tubulin cytoskeleton, the spindle organization and the cortical granules will be studied by immunofluorescence and 3D confocal microscopy. The expression of maternal factors transcription will be analyzed by RT-PCR. The ploidy will be analysed by multiFISH and/or CGH array.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immature oocytes vitrified before in vitro maturation
Immature oocytes will be vitrified using closed system vitrification with a semiautomatic method. After warming, a maturation culture will be performed during 36 hours
Gavi , Merck® (automated vitrification instrument)
Gavi, Merck ® permits semi-automated vitrification with closed system.
Vitrification
Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
Immature oocytes vitrified after in vitro maturation
A maturation culture of immature oocytes will be performed in vitro during 36 hours. After IVM, mature oocytes will be vitrify in closed system by a semi-automatic method.
Gavi , Merck® (automated vitrification instrument)
Gavi, Merck ® permits semi-automated vitrification with closed system.
Vitrification
Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
Fresh oocytes
The culture of immature oocytes will be performed during 36 hours
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gavi , Merck® (automated vitrification instrument)
Gavi, Merck ® permits semi-automated vitrification with closed system.
Vitrification
Group 1: immature ovocytes vitrified before IVM; Group 2: immature oocytes vitrified after IVM; Group3: fresh immature oocytes treated by IVM (without vitrification, control group).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Immature oocytes
* Without ovulation pathologies
Exclusion Criteria
* Endometriosis
* Ovulatory disease
18 Years
37 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Florence BRUGNON
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Clermont-Ferrand
Clermont-Ferrand, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Chaput L, Dollet S, Eymard-Pierre E, Pereira B, Lucas C, Gremeau AS, Tchirkov A, Marteil G, Brugnon F. Analysis of maturation dynamics and oocyte nuclear quality after rescue-IVM and semi-automated vitrification. Hum Reprod. 2025 Jul 1;40(7):1344-1356. doi: 10.1093/humrep/deaf078.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHU-393
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.